Effects of MTBE on Leydig cell tumors in Sprague-Dawley rats: Range of possible Poly-3 results

Regulatory Toxicology and Pharmacology

Volumn 49, Issue 1, 2007, Pages 53-62

  Goodman, Julie E ^a   Gaylor, David ^b   Beyer, Leslie A ^a   Rhomberg, Lorenz R ^a   Beck, Barbara D ^a  

^a GRADIENT   (United States)

^b Gaylor and Associates LLC   (United States)

Author keywords

Leydig cell tumor; MTBE; Poly 3 analysis; Prevalence analysis; Sprague Dawley rats

Indexed keywords

ETHER DERIVATIVE; GASOLINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOASSAY; CANCER INCIDENCE; CANCER SURVIVOR; CONTROLLED STUDY; FEEDING; FEMALE; LEYDIG CELL TUMOR; MALE; NONHUMAN; OVERALL SURVIVAL; PREVALENCE; PRIORITY JOURNAL; RAT; SPRAGUE DAWLEY RAT; STATISTICAL SIGNIFICANCE; SURVIVAL RATE;

ANIMALIA; RATTUS;

EID: 34548378995     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2007.05.002     Document Type: Article

References (35)

1. Agency for Toxic Substances and Disease Registry (ATSDR), 1996. Toxicological profile for methyl tert-butyl ether. Research Triangle Institute: Research Triangle Park, VA.
2. Bailer A., and Portier C. Effects of treatment-induced mortality and tumor-induced mortality on tests for carcinogenicity in small samples. Biometrics 44 2 (1988) 417-431
3. Belpoggi F., Soffritti M., and Maltoni C. Methyl-tertiary-butyl ether (MTBE)-a gasoline additive-causes testicular and lymphohaematopoietic cancers in rats. Toxicol. Ind. Health 11 (1995) 119-149
4. Belpoggi F., Soffritti M., Filippini F., and Maltoni C. Results of long-term experimental studies on the carcinogenicity of methyl tert-butyl ether. Ann. NY Acad. Sci. 837 (1997) 77-95
5. Belpoggi F., Soffritti M., and Maltoni C. Pathological characterization of testicular tumors and lymphomas-leukaemias, and of their precursors observed in Sprague-Dawley rats exposed to methyl-tertiary-butyl-ether (MTBE). Eur. J. Oncol. 3 (1998) 201-206
6. Bird M.G., Burleigh-Flayer H.D., Chun J.S., Douglas J.F., Kneiss J.J., and Andrews L.S. Oncogenicity studies of inhaled methyl tertiary-butyl ether (MTBE) in CD-1 mice and F-344 rats. J. Appl. Toxicol. 17 (1997) S45-S55
7. Chun, J.S., Burleigh-Flayer, H.D., Kintigh, W.J., 1992, November 13. Methyl tertiary butyl ether: Vapor inhalation oncogenicity study in Fischer 344 rats. Export, PA: Bushy Run Research Center.
8. Christensen A.K., and Peacock K.C. Increase in Leydig cell number in testes of adult rats treated chronically with an excess of human chorionic gonadotropin. Biol. Reprod. 22 2 (1980) 383-391
9. Clegg E.D., Cook J.C., Chapin R.E., Foster P.M., and Daston G.P. Leydig cell hyperplasia and adenoma formation: mechanisms and relevance to humans. Reprod. Toxicol. 22 1 (1997) 107-121
10. Cook J.C., Klinefelter G.R., Hardisty J.F., Sharpe R.M., and Foster P.M.D. Rodent Leydig cell tumorigenesis: a review of the physiology, pathology, mechanisms, and relevance to humans. Crit. Rev. Toxicol. 29 2 (1999) 169-261
11. Cruzan, G., Borghoff, S.J., de Peyster, A., Hard, G.C., McClain, M., McGregor, D.B., Thomas, M.G. 2006, November 2. Methyl tertiary-butyl ether mode of action for cancer endpoints in rodents. Regul Toxicol Pharmacol. [Epub ahead of print].
12. Davies T.S., Lynch B.S., Monro A.M., Munro I.C., and Nestmann E.R. Rodent carcinogenicity tests need be no longer than 18 months: an analysis based on 210 chemicals in the IARC monographs. Food Chem. Toxicol. 38 2-3 (2000) 219-235
13. de Peyster A., MacLean K.J., Stephens B.A., Ahern L.D., Westover C.M., and Rozenshteyn D. Subchronic studies in Sprague-Dawley rats to investigate mechanisms of MTBE-induced Leydig cell cancer. Toxicol. Sci. 72 1 (2003) 31-42
14. European Centre for Ecotoxicity and Toxicology of Chemicals (ECETOC), 2003. Risk assessment report for existing substances: methyl tertiary-butyl ether (Special Report No. 17). Brussels: European Centre for Ecotoxicity and Toxicology of Chemicals, 288p.
15. European Chemicals Bureau (ECB), 2002. European Union risk assessment report: tert-butyl methyl ether (CAS No: 1634-04-4) (European Chemicals Bureau 3rd Priority list, volume 19). Luxembourgh: Office for Official Publications of the EC.
16. European Food Safety Authority (EFSA), 2006. Opinion of the scientific panel on food additives, flavourings, processing aids, and materials in contact with food (AFC) on a request from the commission related to a new long-term carcinogenicity study on aspartame. Question number EFSA-Q-2005-122. Eur. Food Saf. Author. J., 356, 1-44. Retrieved from http://www.efsa.europa.eu/science/afc/afc_opinions/1471/afc_op_ej356_aspartame_en2.pdf.
17. Giknis M.L.A., and Clifford C.B. Compilation of spontaneous neoplastic lesions and survival in CRL:CD (SD) rats from control groups (2004), Charles River Laboratories, Cambridge, MA 28p, March.
18. Hard G.C., and Seely J.C. Recommendations for the interpretation of renal tubule proliferative lesions occurring in rat kidneys with advanced chronic progressive nephropathy (CPN). Toxicol. Pathol. 33 6 (2005) 641-649
19. Haseman J.K. A reexamination of false-positive rates for carcinogenesis studies. Fundam. Appl. Toxicol. 3 4 (1983) 334-339
20. Haseman J.K. Commentary on 'Statistical methods for marcinogenicity studies. Toxicol. Pathol. 30 3 (2002) 405-408
21. Haseman J.K., Arnold J., and Eustis S.L. Tumor incidences in Fischer 344 rats: NTP historical data. In: Boorman G.A., Eustis S.L., Elwell M.R., Montgomery C.A., and MacKenzie W.F. (Eds). Pathology of the Fischer Rat: Reference and Atlas (1990), Academic Press, San Diego, CA 555-564
22. Hoel D.G., and Walburg H.E. Statistical analysis of survival experiments. J. Nat. Canc. Inst. 49 2 (1972) 361-372
23. Interagency Regulatory Liaison Group (IRLG), 1979. Scientific bases for identification of potential carcinogens and estimation of risks. J. Nat. Cancer Inst., 244(25).
24. International Agency for Research on Cancer (IARC), 1999. IARC monographs on the evaluation of carcinogenic risks to humans: Volume 73: Some chemicals that cause tumours of the kidney or urinary bladder in rodents and some other substances (IARC Monograph No. 73). Geneva: World Health Organization (WHO).
25. Maronpot R.R. Who will have the last word?. Toxicol. Pathol. 30 3 (2002) 297
26. McGregor D. Methyl tertiary-butyl ether: studies for potential human health hazards. Crit. Rev. Toxicol. 36 4 (2006) 319-358
27. Miller R.A., and Nadon N.L. Principles of animal use for gerontological research. J. Gerontol. A, Biolog. Sci. Med. Sci. 55 3 (2000) B117-B123
28. National Toxicology Program (NTP), 2004. Descriptions of NTP study types: Expanded overview. Retrieved July 7, 2006 from http://ntp-server.niehs.nih.gov/ntpweb/index.cfm?objectid=72015E2C-BDB7-CEBA-F17F9ACA7AE5346D.
29. Peto Analysis Working Group of STP. (2001). Draft recommendations on classification of rodent neoplasms for Peto analysis. Toxicol. Pathol., 29(2), 265-268.
30. Prentice D.E., and Meikle A.W. A review of drug-induced Leydig cell hyperplasia and neoplasia in the rat and some comparisons with man. Hum. Exp. Toxicol. 14 (1995) 562-572
31. Robinson M., Bruner R.H., and Olson G.R. Fourteen- and ninety-day oral toxicity studies of methyl tertiary-butyl ether in Sprague-Dawley rats. J. Am. Coll. Toxicol. 9 5 (1990) 525-540
32. Soffritti M., Belpoggi F., Minardi F., and Maltoni C. Ramazzini Foundation cancer program: history and major projects, life-span carcinogenicity bioassay design, chemicals studied, and results. Ann. NY Acad. Sci. 98 2 (2002) 26-45
33. US Environmental Protection Agency (US EPA), 1997. Drinking water advisory: Consumer acceptability advice and health effects analysis on methyl tertiary-butyl ether (MtBE) (EPA-822-F-97-009). Office of Water: Washington, DC.
34. US Food and Drug Administration (US FDA), Center for Drug Evaluation and Research, 2001. Guidance for industry: Statistical aspects of the design, analysis, and interpretation of chronic rodent carcinogenicity studies of pharmaceuticals. Retrieved November 18, 2006 from http://www.fda.gov/Cder/guidance/815dft.htm.
35. Williams T.M., Cattley R.C., and Borghoff S.J. Alterations in endocrine responses in male Sprague-Dawley rats following oral administration of methyl tert-butyl ether. Toxicol. Sci. 54 (2000) 168-176